The Trial That Was Stopped Early: Beta-Carotene and Vitamin A in Smokers
CARET gave smokers 30mg beta-carotene plus 25,000 IU retinyl palmitate daily. Lung cancer went up 28% and the trial was halted before it finished.
Written by the Biostacks Team
Not medical advice. This content is for educational purposes only and is not a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or combining any supplement or medication.
Flagged in Biostacks
Biostacks flags this automatically.
Add Beta-Carotene and Vitamin A to your stack and Biostacks checks for this interaction in real time.
Beta-carotene and vitamin A are usually discussed as the same nutrient in two forms. In one specific population, taking both at supplemental doses produced a result nobody was expecting, and it ended the study.
Two forms that behave differently
Preformed vitamin A, retinol and its ester retinyl palmitate, comes from liver, dairy, eggs, and supplements. The body absorbs it directly and stores the surplus. There is no brake on that, which is why preformed vitamin A can accumulate to toxic levels.
Beta-carotene is a provitamin. It has to be cleaved into retinal before it becomes vitamin A, and the enzyme that does the cleaving is downregulated when stores are already full. That regulation is the reason eating a lot of carrots turns your palms orange rather than causing vitamin A toxicity.
On paper this makes beta-carotene the safer form. CARET tested the two together.
What CARET found
The Beta-Carotene and Retinol Efficacy Trial enrolled 18,314 people at elevated lung cancer risk: current and former smokers, and workers with asbestos exposure. They received 30mg of beta-carotene and 25,000 IU of retinyl palmitate daily, against placebo. The hypothesis was that antioxidant supplementation would lower cancer incidence.
Lung cancer incidence in the treatment arm was 28 percent higher than in placebo. Lung cancer deaths were 46 percent higher. Overall mortality rose as well. The trial was stopped 21 months ahead of schedule in January 1996 because continuing was no longer defensible.
The Finnish ATBC trial, running in a similar population with 20mg of beta-carotene, had already reported an 18 percent increase in lung cancer incidence. Two independent studies, pointing the same way, in the same kind of participant.
The smoking specificity
This is where the finding gets narrow rather than general. Trials of beta-carotene in populations that were largely non-smoking, including the Physicians’ Health Study, found no such increase.
The leading explanation is that beta-carotene behaves differently in a lung that is exposed to cigarette smoke. The high oxygen tension and oxidative environment there favour breakdown products of beta-carotene that appear to promote rather than prevent carcinogenesis, and high doses supply more of the parent molecule to break down.
Whether the added retinyl palmitate contributed independently is not resolved by CARET’s design, since both were given together.
What it means in practice
Supplemental beta-carotene at CARET-level doses is not something for current or former smokers, or for people with significant asbestos exposure. That is the durable conclusion, and it holds regardless of whether preformed vitamin A is alongside it.
For everyone else the picture is undramatic, but the dose logic still applies. High dose beta-carotene stacked on top of preformed vitamin A from a multivitamin, a cod liver oil capsule, and a beauty formula adds up in a way no single label shows. Carotenoids from food have never been implicated in any of this.
Reference
- Office of Dietary Supplements, National Institutes of Health. "Vitamin A and Carotenoids: Fact Sheet for Health Professionals." ods.od.nih.gov